Enoxamed Study in the Treatment of Acute Coronary Syndromes
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Because of their anti-Xa and ease of administration activity, the Low molecular weight
heparin represent an attractive alternative to the unfractionated heparin. Several clinical
trials have demonstrated that Low molecular weight heparin was more effective than
Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the
most studied. Its use is recommended.
Demonstrate that Enoxamed® is comparable to that of Lovenox® in the anti-Xa activity action.